BP raises 1.06 billion dollars selling Aker BP stake
BP sold 5 percent of Aker BP at 311 Norwegian kroner per share on November 5, raising gross proceeds of about 9.83 billion kroner, or 1.06 billion dollars.
Every story, newest first.
BP sold 5 percent of Aker BP at 311 Norwegian kroner per share on November 5, raising gross proceeds of about 9.83 billion kroner, or 1.06 billion dollars.
French prosecutors have opened an investigation into the bogus bomb threats against dozens of European flights, aimed at finding who sent the emails and whether they have links to foreign powers.
Blackstone announced the final close of its fourth institutional European senior direct lending fund on November 4, with about 13 billion euros of investable capital across the strategy including anticipated leverage.
Minutes of the Bank of Japan's September 17 to 18 meeting, published November 5, show board members debating whether the pace of rate rises may need to accelerate if prices overshoot, after voting 7 to 2 to lift the policy rate to 1.25 percent.
Reported attacks that damaged or destroyed water and sanitation systems in conflict zones rose threefold between 2021 and 2025, from fewer than 45 incidents in eight countries to more than 135 in 15 countries, UNICEF said in a report released Thursday.
Atlassian fiscal first quarter revenue rose 24 percent to 1.772 billion dollars and beat estimates, but the shares fell more than 17 percent after hours on a forecast for slower subscription growth.
More than half of proposed LNG to power projects in the Philippines, Vietnam, Thailand and Bangladesh, worth 67.8 billion dollars, have been scrapped or stalled since 2021, IEEFA said on November 5.
Abstracts published Wednesday for the American Society of Hematology meeting show Johnson and Johnson's trispecific ramantamig produced minimal residual disease negativity in all 20 evaluable patients after three cycles, with AbbVie, Innovent and Shanghai Xianxiang also reporting high early response rates.
AngloGold Ashanti will invest $750 million to $900 million over three years expanding Geita, Siguiri and Cuiaba, targeting 300,000 to 450,000 extra ounces a year by the end of the decade.
A real world study of 544,103 adults published this week found patients starting Amgen's Repatha had a 20 percent lower rate of fatal or nonfatal heart attack than patients starting ezetimibe, with a hazard ratio of 0.80.